DDL 2026: Inhaled and Nasal Drug Product Research from Intertek

Collaborative inhaled and nasal drug delivery research at DDL 2026

Intertek scientists have contributed to two collaborative research projects being presented at DDL, alongside experts from industry and academia.
Questions about the research? Contact our team to discuss the work and its relevance to inhaled and nasal drug product development.

Poster and Podium Presentation from the EPAG Nasal team:
Towards Standardised Compendial Testing of Nasal Products: Multi-Laboratory Evaluation of the Kiel Nasal Inlet for Assessment of the %<10 µm Fraction    

This multi-laboratory EPAG Nasal Team study evaluates the Kiel Nasal Inlet as an approach for assessing the fraction of emitted nasal-product material below 10 µm. The work contributes to industry discussion around standardised, reproducible testing methods for nasal products.

Mark Parry

Senior Scientific Director

Mark has over 20 years’ experience in pharmaceutical analysis and formulation development, specialising in orally inhaled and nasal drug products (OINDPs). His expertise spans product and formulation development for novel and generic products, method development and validation, stability studies, pharmaceutical development, and clinical trial manufacturing..

Our team of experts will be available at our booth to discuss how we support development projects for both small and large molecules across all respiratory delivery technology platforms. Get in touch now to arrange a meeting. Key themes for DDL2026 discussions include:

• Formulation development - including particle engineering approaches
• Specialist support for biologics and DNA based medicines with a dedicated suite for testing and characterisation
• Independent device screening and selection
• Clinical manufacturing
• CMC package support
• ICH stability study testing and program management
• QC and GMP Batch Release testing
• In-vitro bioequivalence (IV-BE) studies including
• GMP IV-IVC tools; MDRS, Inhaled Dissolution, Idealised inlet models and realistic breathing profiles for impaction testing

OUR OINDP DEVELOPMENT EXPERTISE
With over 35 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support to help you meet the challenges of your demanding development programs. We provide integrated OINDP development and testing services for both small molecules and biologics through its centres of excellence across Europe. We conduct critical performance and quality testing such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI) and spray pattern/plume geometry. Intertek’s integrated formulation and analytical teams carry out early stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing and device selection support. For large molecule development, comprehensive protein characterisation services supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage can also be provided. Interaction with the device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments. The laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections. 

• Brochure: Inhaled & Nasal Drug Product Development